Results 281 to 290 of about 700,178 (349)

Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion

Journal of NeuroInterventional Surgery, 2021
Background Endovascular therapy (EVT) is effective and safe in patients with tandem occlusion. The benefit of intravenous thrombolysis (IVT) prior to EVT in acute tandem occlusion is debatable. Objective To compare EVT alone with EVT plus IVT in patients
M. Anadani, G. Marnat, A. Consoli, P. Papanagiotou, R. Nogueira, A. Spiotta, R. Bourcier, M. Kyheng, J. Labreuche, A. Siddiqui, M. Ribó, A. D. de Havenon, U. Fischer, I. Sibon, C. Dargazanli, C. Arquizan, C. Cognard, J. Olivot, R. Anxionnat, G. Audibert, M. Mazighi, R. Blanc, B. Lapergue, S. Richard, B. Gory   +24 more
semanticscholar   +1 more source

Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke

Annals of Neurology, 2022
Intravenous thrombolysis (IVT) with tenecteplase has been associated with better clinical outcomes in acute ischemic stroke (AIS) patients with confirmed large vessel occlusions compared to IVT with alteplase. However, the utility of tenecteplase for the
G. Tsivgoulis, A. Katsanos, Christos Christogiannis, B. Faouzi, D. Mavridis, A. Dixit, L. Palaiodimou, D. Khurana, Marco Petruzzellis, K. Psychogios, M. MacLeod, N. Ahmed   +11 more
semanticscholar   +1 more source

Cystatin C and intravenous thrombolysis

European Journal of Neurology, 2021
With great interest, we read the recent original article written by Zihan Chang et al1 , which was published in European Journal of Neurology. In this multicenter retrospective case-control study, the authors found that elevated serum Cystatin C may be associated with unfavorable clinical outcomes after intravenous tissue plasminogen activator therapy,
Meidi Peng, Yupei Chen, Guiling Geng
openaire   +2 more sources

Beyond Intravenous Thrombolysis

CNS Spectrums, 2007
ABSTRACTThe National Institute of Neurological Disorders and Stroke trial of recombinant tissue plasminogen activator has been considered a landmark study in the acute treatment of ischemic stroke. Unfortunately, only a small percentage of all ischemic stroke patients presents to the hospital in time to receive the drug.
Kiwon, Lee, Srikanth, Muppidi, Farhan, Siddiq, Carissa, Pineda, David G, Brock, Rodney D, Bell   +5 more
openaire   +2 more sources

Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1

International Journal of Stroke, 2021
Background Up to 30% of stroke patients initially presenting with non-disabling or mild deficits may experience poor functional outcome. Despite, intravenous thrombolysis remains controversial in this subgroup of stroke patients due to its uncertain risk
M. Sykora, S. Krebs, F. Simader, T. Gattringer, S. Greisenegger, J. Ferrari, A. Bernegger, A. Posekany, W. Lang   +8 more
semanticscholar   +1 more source

Intravenous thrombolysis for acute ischemic stroke: why not?

Current Opinion in Neurology, 2021
Purpose of review The aim of this study was to summarize available evidence regarding the safety and efficacy of intravenous thrombolysis (IVT) using recombinant tissue-plasminogen activator (rt-PA) in acute ischemic stroke (AIS) patients with specific ...
K. Psychogios, G. Tsivgoulis
semanticscholar   +1 more source

Stroke Mimics and Intravenous Thrombolysis

Annals of Emergency Medicine, 2012
The necessity for rapid administration of intravenous thrombolysis in patients with acute ischemic stroke may lead to treatment of patients with conditions mimicking stroke. We analyze stroke patients treated with intravenous thrombolysis in our center to characterize cases classified as stroke mimics.We identified and reviewed all cases with a ...
Meretoja Atte, Strbian Daniel, Silvennoinen H., Putaala J., Piironen K., Happola O., Liebkind R., Atula Sari, Artto V., Meretoja Atte, Strbian Daniel, Silvennoinen H., Putaala J., Piironen K., Happola O., Liebkind R., Atula Sari, Artto V.   +17 more
openaire   +4 more sources

Efficacy and safety of normobaric hyperoxia combined with intravenous thrombolysis on acute ischemic stroke patients

Neurological Research, 2021
Intravenous thrombolysis elevates the prognostic level of acute ischemic stroke (AIS) patients. Normobaric hyperoxia (NBO) delays the progression of the infarct core and promotes neurological recovery.
Na Li, Longfei Wu, Wenbo Zhao, D. Dornbos, Chuanjie Wu, Weili Li, Di Wu, J. Ding, Yuchuan Ding, Yunyan Xie, X. Ji   +10 more
semanticscholar   +1 more source

Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.

New England Journal of Medicine
BACKGROUND Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular reocclusion may occur after intravenous thrombolysis and may be preventable with an antiplatelet agent within the first 24 ...
Chunrong Tao, Tianlong Liu, Tao Cui, Jie Liu, Zongliang Li, Youquan Ren, Xingli Zhao, Fuyou Xie, Jianqiao Li, Hao Wang, Ling-Yan Huang, Jianjun Li, Jianshang Wen, Jianzhong Zeng, Junyong Zhu, Zhide Li, Dajun Li, Xuefeng Hu, Biao Huang, Jing Wang, Chi Zhang, Bin Ye, Yubao Hou, Yanlin Gan, Hong Sun, Fei Guan, Ya Shao, Zongtao Liu, Zehu Ou, Shikai Fan, Yao Wang, Hongjiang Zhai, Chunhua Ni, Hao Wang, Chenggang Zhang, Yan Zhao, Guoping Wang, Yuyou Zhu, Rui Li, Jun Sun, Haiying Hu, Jiangping Cui, Li Wang, Chao Zhang, Jianlong Song, Xiaozhong Jing, Anmo Wang, Jinjing Wang, Peng Xu, Adnan I. Qureshi, Thanh N. Nguyen, R. Nogueira, J. Saver, Wei Hu   +53 more
semanticscholar   +1 more source

Intravenous thrombolysis in Sneddon’s syndrome

Journal of Clinical Neuroscience, 2012
Sneddon's syndrome (SS) is an uncommon disorder, characterized by the association of ischemic stroke and widespread livedo reticularis. The treatment options for SS to prevent stroke recurrence and future disability include antiplatelet therapy, anticoagulation, or immunosuppression.
Jianzhong, Sun, Fanhui, Zhang, Feng, Gao, Jihua, Wang, Magdy, Selim, Min, Lou   +5 more
openaire   +2 more sources